Mira Pharmaceuticals (MIRA) Change in Receivables (2024)
Mira Pharmaceuticals (MIRA) posted Change in Receivables of -$11862.0 for Q1 2024.
Mira Pharmaceuticals (MIRA) Change in Receivables (2024) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 1 years of Change in Receivables data on file, last reported at -$11862.0 in Q1 2024.
- Quarterly Change in Receivables changed N/A year-over-year to -$11862.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was -$11862.0 (changed N/A YoY) and the FY2024 annual result came in at -$11862.0, down 200.0% from the prior year.
- Change in Receivables held at -$11862.0 in Q1 2024 per MIRA's latest filing.
- The five-year high for Change in Receivables was -$11862.0 in Q1 2024, with the low at -$11862.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 595.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -87.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -413.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -134.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -11,862.00 |
| Mar 31, 2024 | -11,862.00 |